Infliximab in Crohn's disease: early and long-term treatment

Digestive and Liver Disease

Volumn 40, Issue SUPPL. 2, 2008, Pages

  Armuzzi, A ^a   De Pascalis, B ^a   Fedeli, P ^a   De Vincentis, F ^a   Gasbarrini, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Biological therapy; Crohn's disease; Infliximab; Treatment strategies

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; GAMMA INTERFERON ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CLINICAL TRIAL; COLON RESECTION; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY INTERVENTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MONOTHERAPY; PRACTICE GUIDELINE; PREDICTION; RELAPSE; REMISSION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; PRACTICE GUIDELINES AS TOPIC;

EID: 45849091079     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(08)60537-X     Document Type: Article

References (87)

1. Cobrin G., and Abreu M. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 206 (2005) 277-295
2. Sands B., Arsenault J., Rosen M., Alsahli M., Bailen L., Banks P., et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 98 (2003) 2712-2718
3. Wolters F., Russel M., and Stockbrugger R. Systematic review: has disease outcome in Crohn's disease changed during the last four decades?. Aliment Pharmacol Ther 20 (2004) 483-496
4. Munkholm P., Langholz E., Davidsen M., and Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30 (1995) 699-706
5. Binder V., Hendriksen C., and Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut 26 (1985) 146-150
6. Korzenik J., and Podolsky D. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 5 (2006) 197-209
7. Travis S., Stange E., Lémann M., Oresland T., Chowers Y., Forbes A., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl 1 (2006) i16-i35
8. Clark M., Colombel J., Feagan B., Fedorak R., Hanauer S., Kamm M., et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 133 (2007) 312-339
9. Nielsen O., and Munck L. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 160-170
10. Lal S., and Steinhart A. Antibiotic therapy for Crohn's disease: a review. Can J Gastroenterol 20 (2006) 651-655
11. Otley A., and Steinhart A. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 4 (2005) CD000296
12. Summers R., Switz D., Sessions Jr. J., Becktel J., Best W., Kern Jr. F., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77 (1979) 847-869
13. Malchow H., Ewe K., Brandes J., Goebell H., Ehms H., Sommer H., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86 (1984) 249-266
14. Modigliani R., Mary J., Simon J., Cortot A., Soule J., Gendre J., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thera-peutique des Affections Inflammatoires Digestives. Gastroenterology 98 (1990) 811-818
15. Steinhart A., Ewe K., Griffiths A., Modigliani R., and Thomsen O. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 4 (2003) CD00031
16. Rutgeerts P. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 15 (2001) 1515-1525
17. Present D., Korelitz B., Wisch N., Glass J., Sachar D., and Pasternack B. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302 (1980) 981-987
18. Candy S., Wright J., Gerber M., Adams G., Gerig M., and Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37 (1995) 674-678
19. Bouhnik Y., Lemann M., Mary J., Scemama G., Tai R., Matuchansky C., et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347 (1996) 215-219
20. Feagan B., Fedorak R., Irvine E., Wild G., Sutherland L., Steinhart A., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342 (2000) 1627-1632
21. Feagan B., Rochon J., Fedorak R., Irvine E., Wild G., Sutherland L., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 332 (1995) 292-297
22. Silverstein M., Loftus E., Sandborn W., Tremaine W., Feagan B., Nietert P., et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gas-troenterology 117 (1999) 49-57
23. Faubion Jr. W., Loftus E., Harmsen W., Zinsmeister A., and Sandborn W. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
24. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., and Gendre J. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54 (2005) 237-241
25. Rutgeerts P., Van Assche G., and Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 23 (2006) 451-463
26. United States Food and Drug Administration. About the Center for Biologic Evaluation and Research (CBER) (July 19, 2007). Available at: http//www.fda.gov/cber/about.htm Accessed August 8 2007.
27. Scallon B., Moore M., Trinh H., Knight D., and Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant trans-membrane TNF-alpha and activates immune effector functions. Cy-tokine 7 (1995) 251-259
28. Van den Brande J., Braat H., van den Brink G., Versteeg H., Bauer C., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
29. Di Sabatino A., Pender S., Jackson C., Prothero J., Gordon J., Picariello L., et al. Functional modulation of Crohn's disease myofi-broblasts by anti-tumor necrosis factor antibodies. Gastroenterology 133 (2007) 137-149
30. Targan S., Hanauer S., van Deventer S., Mayer L., Present D., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
31. Present D., Rutgeerts P., Targan S., Hanauer S., Mayer L., van Hogezand R., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
32. Hanauer S., Feagan B., Lichtenstein G., Mayer L., Schreiber S., Colombel J., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
33. Rutgeerts P., Feagan B., Lichtenstein G., Mayer L., Schreiber S., colombel J., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
34. Sands B., Anderson F., Bernstein C., Chey W., Feagan B., Fedorak R., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
35. Hanauer S., Sandborn W., Rutgeerts P., Fedorak R., Lukas M., Macintosh D., et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
36. Colombel J., Sandborn W., Rutgeerts P., Enns R., Hanauer S., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
37. Sandborn W., Rutgeerts P., Enns R., Hanauer S., Colombel J., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med 146 (2007) 829-838
38. Schreiber S., Rutgeerts P., Fedorak R., Khaliq-Kareemi M., Kamm M., Boivin M., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
39. Sandborn W., Feagan B., Stoinov S., Honiball P., Rutgeerts P., Mason D., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
40. Schreiber S., Khaliq-Kareemi M., Lawrance I., Østergaard Thomsen O., Hanauer S., McColm J., et al. Maintenance therapy with cer-tolizumab pegol for Crohn's disease. N Engl J Med 357 (2007) 239-250
41. Gartlehner G., Hansen R., Jonas B., Thieda P., and Lohr K. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33 (2006) 2398-2408
42. Goekoop-Ruiterman Y., de Vries-Bouwstra J., Allaart C., van Zeben D., Kerstens P., Hazes J., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
43. U.S. Food and Drug Administration, and Center for Drug Evaluation and Research. Questions and answers on Remicade/FDA action (May 19, 2006). Available at: http://www.fda.gov/cder/drug/infopage/infliximab/qa.htm Accessed August 8, 2007.
44. Tysabri (natalizumab) full prescribing information (June 5, 2007). Available at: http://www.tysabri.com/TYSABRI-pi.pdf Accessed August 8, 2007.
45. Boers M., Verhoeven A., Markusse H., van de Laar M., West-hovens R., van Denderen J., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (1997) 309-318
46. Bathon J., Martin R., Fleischmann R., Tesser J., Schiff M., Keystone E., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med 343 (2000) 1586-1593
47. Breedveld F., Emery P., Keystone E., Patel K., Furst D., Kalden J., et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63 (2004) 149-155
48. St Clair E., van der Heijde D., Smolen J., Maini R., Bathon J., Emery P., et al. Combination of infliximab and methotrexate therapy for early active rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3423-3443
49. Breedveld F., Weisman M., Kavanaugh A., Cohen S., Pavelka K., van Vollenhoven R., et al. The Premier study: A multicenter, randomized, double-blind, clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adali-mumab alone in patients with aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
50. Hanauer S. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 493
51. Caprilli R., Angelucci E., and Cocco A. Early or late guided missile in the treatment of Crohn's disease. Dig Liver Dis 37 (2005) 973-979
52. Oldenburg B., and Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up. Curr Opin Gastroenterol 23 (2007) 395-399
53. Louis E., Collard A., Oger A., Degroote E., Aboul Nasr El Yafi F., and Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49 (2001) 777-782
54. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 8 (2002) 244-250
55. Munkholm P., Langholz E., Davidsen M., and Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35 (1994) 360-362
56. Kandiel A., Fraser A., Korelitz B., Brensinger C., and Lewis J. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
57. Lichtenstein G., Feagan B., Cohen R., Salzberg B., Diamond R., Chen D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroen-terol Hepatol 4 (2006) 621-630
58. Hansen R., Gartlehner G., Powell G., and Sandler R. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 5 (2007) 729-735
59. Mackey A., Green L., Liang L., Dinndorf P., and Avigan M. Hep-atosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroen-terol Nutr 44 (2007) 265-267
60. Jaspers G., Verkade H., Escher J., de Ridder L., Taminiau J., and Rings E. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis 12 (2006) 831-836
61. Lionetti P., Bronzini F., Salvestrini C., Bascietto C., Canani R., Dé Angelis G., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 18 (2003) 425-431
62. Kugathasan S., Werlin S., Martinez A., Rivera M., Heikenen J., and Binion D. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 95 (2000) 3189-3194
63. Markowitz J., Grancher K., Kohn N., Lesser M., and Daum F. A multicen-ter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119 (2000) 895-902
64. Lemann M., Mary J., Duclos B., Veyrac M., Dupas J., Delchier J., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroen-terology 130 (2006) 1054-1061
65. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Jo-hanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132 (2007) 863-873
66. Schreiber S., Reinisch W., Colombel J., Sandborn W., Hommes D., Li J., et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 132 (2007) A147
67. Sandborn W., Colombel J., Panes J., Scholmerich J., McColm J., and Schreiber S. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn's disease: data from PRECiSE 2. Am J Gas-troenterol 101 (2006) S454-S455
68. Hommes D., Baert F., van Assche G., Caenepeel F., Vergauwe P., De Vos M., et al. The ideal management of Crohns Disease: top down versus step up strategies, a randomized controlled trial. Gastroen-terology 130 (2006) A-108-A-109
69. D'Haens G., Hommes D., Baert F., De Vos M., Caenepeel F., Van Assche G., et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology 130 (2006) A-110
70. Rutgeerts P., Diamond R., Bala M., Olson A., Lichtenstein G., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 (2006) 433-442
71. Feagan B., Panaccione R., Sandborn W., D'Haens G., Schreiber S., Rutgeerts P., et al. An evaluation of adalimumab on the risk of hospitalization in patients with Crohn's disease, data from CHARM. Gastroenterology 132 Suppl 1 (2007) A-513
72. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J., and Cosnes J. Predictors of Crohn's disease. Gastroenterology 130 (2006) 650-656
73. Sahmoud T., Hoctin-Boes G., Modigliani R., Bitoun A., Colombel J., Soule J., et al. Identifying patients with high risk of relapse in quiescent Crohn's disease. The GETAID group. Gut 37 (1995) 811-818
74. Brignola C., Campieri M., Bazzocchi G., Farruggia P., Tragnone A., and Lanfranchi G. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 8 (1986) 1490-1494
75. Wolters F., Russel M., Sijbrandij J., Ambergen T., Odes S., Riis L., et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 55 (2006) 1124-1130
76. Rubenstein J., Chong R., and Cohen R. Infliximab decreases resource use among patients with Crohn's disease. Am J Gastroenterol 35 (2002) 151-156
77. Wong J., Loftus E., Sandborn W., and Feagan B. Estimating cost-effectiveness of maintenance infliximab for chronic active Crohn's disease from Accent 1. Gut 52 Suppl 1 (2003) A54
78. Jewell D., Satsangi J., Lobo A., Probert C., Forbes A., Ghosh S., et al. Infliximab use in Crohn's disease: impact on health care resources in UK. Eur J Gastroenterol Hepatol 17 (2005) 1047-1052
79. Fraser A., Orchard T., and Jewell D. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50 (2002) 485-489
80. Lemann M., Mary J., Colombel J., Duclos B., Soule J., Lerebours E., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128 (2005) 1812-1818
81. Shih E., Bayless T., and Harris M. Maintenance of long-term response to infliximab over 1 to 5 years in Crohn's disease including shortening dosing intervals or increasing dosage. Gastroenterology 126 Suppl 2 (2005) A-631
82. Fedorak R., Bitton A., Hassard P., Vargo A., and Garon E. Infliximab dose in the real-life remains stable over 30 months with favourable bene-fit:risk profile in CD. Gastroenterology 132 Suppl 1 (2007) A-180
83. Armuzzi A., De Pascalis B., Roberto I., Ennas S., De Vincentis F., Guglielmo S., et al. Long-term scheduled therapy with infliximab in inflammatory bowel disease. Gastroenterology 132 Suppl 1 (2007) A-183
84. Ridder L., Rings E., Benninga M., Taminiau J., Kneepkens F., and Escher J. Infliximab in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Gastroenterology 132 Suppl 1 (2007) A-182
85. Schreiber S., Hanauer S., Feagan B., Bloomfield R., Rutgeerts P., and Sandborn W. Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: Precise 3 efficacy results. Gastroenterology 132 Suppl 1 (2007) A-504
86. Colombel J., Schreiber S., Hanauer S., Rutgeerts P., and Sandborn W. Long-term tolerability of subcutaneous certolizumab pegol in active Crohn's disease: results from Precise 3 and 4. Gastroenterology 132 Suppl 1 (2007) A-503
87. Domènech E., Hinojosa J., Nos P., Garcia-Planella E., Cabré E., Bernal I., et al. Clinical evolution of luminal and perianal Crohn's disease after inducine remission with infliximab: how long should patients be treated?. Aliment Pharmacol Ther 22 (2005) 1107-1113